Jiangsu Hengrui Medicine Co Ltd Asset Resilience Ratio
Jiangsu Hengrui Medicine Co Ltd asset resilience ratio. Jiangsu Hengrui Medicine Co Ltd (600276) has an Asset Resilience Ratio of 0.16% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Jiangsu Hengrui Medicine Co Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Jiangsu Hengrui Medicine Co Ltd (2000–2024)
Asset resilience ratio of Jiangsu Hengrui Medicine Co Ltd from 2000 to 2024. This chart shows how Jiangsu Hengrui Medicine Co Ltd's Asset Resilience Ratio has changed over time. See 600276 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Jiangsu Hengrui Medicine Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Jiangsu Hengrui Medicine Co Ltd's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥111.45 Million | 0.16% |
| Total Liquid Assets | CN¥111.45 Million | 0.16% |
Asset Resilience Insights
- Limited Liquidity: Jiangsu Hengrui Medicine Co Ltd maintains only 0.16% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Jiangsu Hengrui Medicine Co Ltd Industry Peers by Asset Resilience Ratio
Compare Jiangsu Hengrui Medicine Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
|
Zhejiang Medicine Co Ltd
SHG:600216 |
Drug Manufacturers - Specialty & Generic | 1.85% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.09% |
|
Chongqing Pharscin Pharmaceutical Co Ltd
SHE:002907 |
Drug Manufacturers - Specialty & Generic | 14.54% |
Jiangsu Hengrui Medicine Co Ltd Asset Resilience Ratio by Year (2000–2024)
Jiangsu Hengrui Medicine Co Ltd asset resilience ratio by year from 2000 to 2024. The table below shows the annual Asset Resilience Ratio data for Jiangsu Hengrui Medicine Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.55% | CN¥273.34 Million ≈ $40.00 Million |
CN¥50.14 Billion ≈ $7.34 Billion |
+0.32pp |
| 2023-12-31 | 0.23% | CN¥99.05 Million ≈ $14.49 Million |
CN¥43.78 Billion ≈ $6.41 Billion |
-6.29pp |
| 2022-12-31 | 6.52% | CN¥2.76 Billion ≈ $403.95 Million |
CN¥42.36 Billion ≈ $6.20 Billion |
-6.45pp |
| 2021-12-31 | 12.96% | CN¥5.09 Billion ≈ $744.88 Million |
CN¥39.27 Billion ≈ $5.75 Billion |
-3.24pp |
| 2020-12-31 | 16.21% | CN¥5.63 Billion ≈ $823.55 Million |
CN¥34.73 Billion ≈ $5.08 Billion |
-14.71pp |
| 2019-12-31 | 30.92% | CN¥8.52 Billion ≈ $1.25 Billion |
CN¥27.56 Billion ≈ $4.03 Billion |
-0.67pp |
| 2018-12-31 | 31.59% | CN¥7.06 Billion ≈ $1.03 Billion |
CN¥22.36 Billion ≈ $3.27 Billion |
+6.36pp |
| 2017-12-31 | 25.22% | CN¥4.55 Billion ≈ $665.84 Million |
CN¥18.04 Billion ≈ $2.64 Billion |
+14.55pp |
| 2016-12-31 | 10.68% | CN¥1.53 Billion ≈ $223.91 Million |
CN¥14.33 Billion ≈ $2.10 Billion |
+7.13pp |
| 2008-12-31 | 3.55% | CN¥80.04 Million ≈ $11.71 Million |
CN¥2.25 Billion ≈ $329.88 Million |
-9.90pp |
| 2007-12-31 | 13.45% | CN¥270.88 Million ≈ $39.64 Million |
CN¥2.01 Billion ≈ $294.67 Million |
+12.70pp |
| 2006-12-31 | 0.75% | CN¥10.97 Million ≈ $1.60 Million |
CN¥1.46 Billion ≈ $213.35 Million |
-4.25pp |
| 2003-12-31 | 5.00% | CN¥72.59 Million ≈ $10.62 Million |
CN¥1.45 Billion ≈ $212.28 Million |
-1.01pp |
| 2002-12-31 | 6.02% | CN¥72.49 Million ≈ $10.61 Million |
CN¥1.20 Billion ≈ $176.27 Million |
-4.93pp |
| 2001-12-31 | 10.95% | CN¥122.49 Million ≈ $17.92 Million |
CN¥1.12 Billion ≈ $163.75 Million |
-1.60pp |
| 2000-12-31 | 12.55% | CN¥123.75 Million ≈ $18.11 Million |
CN¥986.27 Million ≈ $144.32 Million |
-- |
About Jiangsu Hengrui Medicine Co Ltd
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. It develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and… Read more